Discovery Texas Interventional Psychiatry Reports Strong Depression Outcomes From TMS Therapy Program

Sep 17, 2026

Among clients with a complete PHQ-9 record, the average depression score fell 73 percent from intake to discharge, with nearly all clients moving into the minimal or mild symptom range

United States, September 17, 2026 -- Discovery Texas Interventional Psychiatry (DTIP) today released outcomes data from its transcranial magnetic stimulation (TMS) therapy program, showing substantial improvement in depression symptoms among clients with a complete PHQ-9 record at both intake and discharge during the reporting period.

Among the 22 clients with a documented PHQ-9 depression score at both intake and discharge, the average score fell from 17.4 to 4.7, a 73 percent reduction. Eighty-six percent of clients achieved a clinical response, defined as at least a 50 percent drop in PHQ-9 score from baseline, and 45 percent reached remission, meaning a discharge score below 5. Ninety-five percent of clients ended treatment in the Minimal or Mild severity range on the PHQ-9 scale, up from just 5 percent at intake.

Nearly every client in the reporting group began treatment in the Moderate-to-Severe range, with six clients entering at the Severe level and 12 at the Moderately Severe level. By discharge, 21 of the 22 clients had moved into the Minimal or Mild bands, the two lowest severity levels on the PHQ-9 scale. No client with a complete record ended treatment with a higher score than they started with.

"These numbers reflect what we see clinically every week: people who felt stuck after trying medication are able to make real, measurable progress with TMS. When 95 percent of our clients leave treatment in the minimal or mild range, that's not an abstraction, that's people getting their lives back."

— Michael Banis, Chief Growth Officer, Discovery MSO

DTIP measures outcomes using the PHQ-9, a validated 9-item screening tool used nationally to track depression severity, scored from 0 to 27. Clinical response is defined per standard convention as a 50 percent or greater reduction from baseline, and remission as a discharge score below 5. The results reflect the 22 clients with a documented PHQ-9 at both intake and discharge during the reporting period; client identities have been removed for this release, and source records are maintained in the clinical chart.

TMS is an FDA-cleared, non-drug treatment for major depressive disorder and treatment-resistant depression that uses magnetic pulses to stimulate areas of the brain associated with mood regulation. It requires no medication or sedation, and most patients remain awake throughout each session and return to their normal daily activities immediately afterward. Individual results vary, and DTIP's care team coordinates with each patient's existing providers throughout the course of treatment.

Depression and substance use disorders frequently occur together, and DTIP continues to coordinate care with fellow Discovery MSO provider Discovery Point Retreat, which treats co-occurring mental health conditions as part of a full continuum of addiction care, so both concerns can be addressed together. DPR clients can access TMS through DTIP as part of that same coordinated care; more information is available on Discovery Point Retreat's TMS therapy page.

Individuals interested in learning whether TMS may be right for them can request a benefits verification at discoverytexasinterventionalpsychiatry.com or call (855) 635-4776 to speak with the DTIP team.

About Discovery Texas Interventional Psychiatry

Discovery Texas Interventional Psychiatry (DTIP) is a provider-led psychiatric practice located at 4306 Capitol Ave, Dallas, TX 75204, serving the Dallas-Fort Worth area with FDA-cleared TMS therapy for adults with major depressive disorder and treatment-resistant depression. DTIP is part of Discovery MSO, LLC, alongside fellow provider Discovery Point Retreat. For more information, visit discoverytexasinterventionalpsychiatry.com.

Contact Info:
Name: Michael Banis
Email: Send Email
Organization: Discovery Texas Interventional Psychiatry
Phone: (855) 635-4776
Website: https://discoverytexasinterventionalpsychiatry.com

Release ID: 89203353

In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.

More News

article.head.headline
Nov 6, 2026
AI stocks climb after trillions wiped from market values

Investors had been selling off tech shares in part due to concerns the Democrat election victory would mean slower AI development.

article.head.headline
Nov 6, 2026
Susie Wiles, Trump’s Chief of Staff, Is Accused of Blocking Health Policies to Attract Donations

In a no-holds-barred interview with Joe Rogan, Calley Means, a former top health adviser, accused Susie Wiles of repeatedly bowing to lobbying pressures and fixating on campaign contributions.

article.head.headline
Nov 6, 2026
They Spent Millions to Keep Their Dream Cruise Afloat. It Died Anyway.

Secrecy, debt and soaring fuel costs all contributed to the Odyssey’s downfall. Here’s an inside look at how the “endless cruise” unraveled.

article.head.headline
Nov 6, 2026
Why the US midterms sparked an AI stock selloff

Fears of more AI regulation appear to have sparked fear among investors, but concerns about the industry have been growing for some time.

article.head.headline
Nov 6, 2026
Tesla Is Ending Production of Its Cybertruck and Refocusing on the Cybercab

Production of the electric trucks will stop in the middle of 2027 to make room for increased production of its autonomous ride-share vehicle, Elon Musk said.

article.head.headline
Nov 6, 2026
What Shaped Anthropic CEO Dario Amodei’s Thinking on A.I.

Some call him a doomer. Others see him as a responsible technologist. Here’s how Dario Amodei’s thinking on artificial intelligence was shaped.

article.head.headline
Nov 6, 2026
Strong Hiring Reinforces a Sturdy Job Market

Unemployment fell in October, extending years of stability for a U.S. work force threated by inflation and artificial intelligence.

article.head.headline
Nov 6, 2026
Food bank to close amid rising costs

A food bank in Goole annouces it will close in January as costs rise and donations drop.

article.head.headline
Nov 6, 2026
Moderna's mRNA flu and flu-COVID combo vaccines have been approved by Health Canada

Health Canada has authorized Moderna's mRNA vaccine for influenza, as well as its combination mRNA vaccine for flu and COVID-19.

article.head.headline
Nov 6, 2026
Winter support for residents facing cost pressures

The plans aim to help more people access food, financial advice and help with heating costs.

article.head.headline
Nov 6, 2026
A.I. Was Supposed to Come for Our Jobs. So Far, Evidence Is Mixed.

White collar industries that are most exposed to artificial intelligence continued to add jobs in October, although that growth has been weak.

article.head.headline
Nov 6, 2026
PM tells firms to publish salaries in job adverts ahead of new law

The government argues the change will help jobseekers and could help to prevent pay discrimination.


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.